in Health care
USFDA accepts Pfizer supplemental new drug applications for BRAFTOVI plus MEKTOVI
New York: Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) for patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. The Prescription Drug User Fee Act […] More
